Overview

Phase III Study in First-line Treatment of Patients With Metastatic Colorectal Cancer Who Are Not Candidate for Intensive Therapy.

Status:
Active, not recruiting

Trial end date:
2022-09-18

Target enrollment:

Participant gender:

Summary

The main purpose of this study is to demonstrate the superiority of S 95005 in combination with bevacizumab over capecitabine in combination with bevacizumab.

Phase:

Phase 3

Details

Lead Sponsor:

Institut de Recherches Internationales Servier

Collaborator:

ADIR, a Servier Group company

Treatments:

Bevacizumab
Capecitabine
Trifluridine